• No results found

Recombinant Factor VIII versus plasma derived Factor VIII in the management of haemophilia A: an examination of the costs and consequences

N/A
N/A
Protected

Academic year: 2019

Share "Recombinant Factor VIII versus plasma derived Factor VIII in the management of haemophilia A: an examination of the costs and consequences"

Copied!
50
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1: Prevalence of Haemophilia A
Table 2 : Current Viruses Giving Rise to Particular Concern in the   Treatment of Haemophilia A
Table 4: Expected Resource Consequences (£s) of Funding rFVIII
TABLE 5:  Patient Characteristics: Expected Level of FVIII Consumption per  Patient per Year and Estimated Annual Marginal Cost per Patient  Associated with a Switch from High Purity pdFVIII to rFVIII
+3

References

Related documents

additional 25.6% and 10% of our HMB and non-HMB teenagers, respectively, that had normal standard platelet function studies (closure times by PFA; LTA) and for whom EM studies

Burt (1992, 2004) used the notion of 'social broker' to describe an actor organising and systematising interactions across loosely connected groups of people ('structural

This was a preliminary study conducted to examine the relationship between psychographic factors (i.e., personal value, risk attitude, and trust) and the purchase of life

WHAT THIS STUDY ADDS: We conducted this study to describe the patient characteristics, clinical – epidemiological pro fi le, and treatment outcomes for pediatric tuberculosis in

HWPQ scores increased in the intervention lines, but decreased in the control lines, yielding a significant intervention effect (P = 0.048). Conclusion : Employee

In 2001, the Department of Human Services produced the resource Environments for Health: Municipal Public Health Planning Framework (Victorian Department of Human Services 2001) to

Collingwood Vic 3066 Tel: 03 9415 6886 Fax: 03 9415 6898 www.carididesign.com.au Designer: Len Caridi Caridi Design Graphic Design Caridi Design Website Design Caridi

Figure 6 cell viability of McF-7 and MDa-MB-231 cells treated with blank F68–Ves micelles, free MIT solution, and F68–Ves/MIT micelles for 24 hours and 48 hours. Note: error